Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ensysce Biosciences Inc (ENSC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ENSC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.23
1 Year Target Price $20.23
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.9% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.31M USD | Price to earnings Ratio 0.02 | 1Y Target Price 20.23 |
Price to earnings Ratio 0.02 | 1Y Target Price 20.23 | ||
Volume (30-day avg) 1 | Beta 0.98 | 52 Weeks Range 1.62 - 14.67 | Updated Date 06/30/2025 |
52 Weeks Range 1.62 - 14.67 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 110.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -109.51% | Operating Margin (TTM) -149.08% |
Management Effectiveness
Return on Assets (TTM) -88.46% | Return on Equity (TTM) -221.97% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value 2515255 | Price to Sales(TTM) 0.85 |
Enterprise Value 2515255 | Price to Sales(TTM) 0.85 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.5 | Shares Outstanding 2370700 | Shares Floating 1136079 |
Shares Outstanding 2370700 | Shares Floating 1136079 | ||
Percent Insiders 0.43 | Percent Institutions 14.9 |
Analyst Ratings
Rating 1 | Target Price 20.23 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ensysce Biosciences Inc
Company Overview
History and Background
Ensysce Biosciences Inc. is a clinical-stage company focused on developing new, safer prescription pain products using its proprietary drug delivery platforms. Founded to address opioid abuse and overdose issues.
Core Business Areas
- Opioid Abuse Deterrence: Developing opioid analgesics with abuse-deterrent properties utilizing the MPARu2122 (Multi-Pill Abuse Resistance) and TAAPu2122 (Trypsin Activated Abuse Protection) platforms.
- Overdose Protection: Developing overdose protection with nafamostat utilizing the BIO-MDu2122 (Bi-phasic Oral delivery of Molecular Dispersion) platform.
Leadership and Structure
Dr. Lynn Kirkpatrick serves as CEO. The company operates with a typical biotech structure, focusing on research, development, and clinical trials. They have a board of directors overseeing the company's strategy and performance.
Top Products and Market Share
Key Offerings
- PF614: An oral oxycodone prodrug designed with the TAAPu2122 technology to be trypsin-activated in the small intestine. Market share is currently 0% as it is in clinical development. Competitors include Purdue Pharma (OxyContin, bankruptcy), Teva Pharmaceutical (generic opioids), and other companies developing abuse-deterrent opioid formulations.
- PF663: A next generation TAAP oxycodone product with an abuse deterrent capsule, designed to bypass IV abuse. Market share is currently 0% as it is in clinical development. Competitors include Purdue Pharma (OxyContin, bankruptcy), Teva Pharmaceutical (generic opioids), and other companies developing abuse-deterrent opioid formulations.
- PF743: Nafamostat-containing opioid antagonist intended to reduce overdose potential. Market share is currently 0% as it is in clinical development. Competitors include companies focused on overdose reversal agents like naloxone.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically the pain management sector, is driven by a high demand for effective and safer analgesics. There is increasing regulatory pressure to develop abuse-deterrent formulations and address the opioid crisis.
Positioning
Ensysce is positioning itself as an innovator in developing safer opioid products with abuse-deterrent and overdose protection technologies. It aims to address unmet needs in pain management while mitigating the risks associated with opioid abuse.
Total Addressable Market (TAM)
The global pain management market is estimated to be in the hundreds of billions of dollars. Ensysce aims to capture a portion of this TAM by offering safer opioid alternatives. However, due to developmental stages, it has not entered the market yet.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery platforms (MPARu2122, TAAPu2122, BIO-MDu2122)
- Focus on abuse-deterrent and overdose protection technologies
- Potential for significant market share if products are approved
- Experienced management team in drug development
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- Potential regulatory hurdles and approval delays
- No current revenue generation
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline to address other pain management needs
- Government incentives and funding for opioid abuse solutions
- Growing demand for safer opioid alternatives
Threats
- Competition from established pharmaceutical companies
- Generic drug competition upon patent expiration
- Changing regulatory landscape
- Clinical trial failures
Competitors and Market Share
Key Competitors
- TEVA
- PFE
- ENDP
Competitive Landscape
Ensysce is a smaller player in the competitive pharmaceutical landscape. Its advantages lie in its novel technology and focus on safer opioid formulations. However, it faces significant competition from larger, more established companies with greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Ensysce has not demonstrated revenue growth due to being a development-stage company.
Future Projections: Future growth depends heavily on the successful completion of clinical trials and regulatory approval of its products. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include advancing PF614, PF663, and PF743 through clinical trials, securing financing for operations, and exploring potential partnerships.
Summary
Ensysce Biosciences is a clinical-stage company with innovative technology targeting safer opioid alternatives. The company's success is dependent on the successful completion of clinical trials and regulatory approval. While its proprietary platforms offer a competitive advantage, it faces risks due to limited financial resources and competition from larger pharmaceutical companies. The company needs to secure partnerships and navigate regulatory hurdles to achieve its market potential. Ensysce looks strong and has potential if their tech works.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ensysce Biosciences Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2018-02-26 | President, CEO & Director Dr. D. Lynn Kirkpatrick Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.ensysce.com |
Full time employees 7 | Website https://www.ensysce.com | ||
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.